Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MorphoSys 4 ADR Representing Ord Shs MPSYF


Primary Symbol: MOR Alternate Symbol(s):  MPHSF

Healthcare Technology Biotechnology Scientific & Technical Instruments
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.


NDAQ:MOR - Post by User

MorphoSys 4 ADR Representing Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(119)
•••
Post by whytestockson Jan 30, 2024 3:30am
114 Views
Post# 35852007

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product
Just In: $MOR MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityPreliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (&#x20AC; 85.0 million) and preliminary gross margin for Monjuvi U.S. net product sales of 69% Anticipated 2024 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million Anticipated 2024 OpEx in the range of &...MOR - MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities